Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway

• Үндсэн зохиолчид: Xiaonan Kang (Зохиогч), Dan Wang (Зохиогч), Lu Zhang (Зохиогч), Teng Huang (Зохиогч), Siyue Liu (Зохиогч), Xiaohui Feng (Зохиогч), Yaoyao Guo (Зохиогч), Ziyin Zhang (Зохиогч), Zhongjing Wang (Зохиогч), Huihui Ren (Зохиогч), Gang Yuan (Зохиогч)
• Формат: Ном
• Хэвлэсэн: BMC, 2023-09-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract Background  Type 2 diabetes (T2D) is an independent risk factor for Alzheimer's disease (AD). Exendin-4 (Ex-4), a widely used glucagon-like peptide-1 receptor agonist drug in the treatment of T2D, has been demonstrated the therapeutic effects on diabetic encephalopathy (DE). Especially...